Equities

Minerva Neurosciences Inc

Minerva Neurosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.21
  • Today's Change0.09 / 4.25%
  • Shares traded17.72k
  • 1 Year change-55.80%
  • Beta0.1092
Data delayed at least 15 minutes, as of Nov 21 2024 20:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Minerva Neurosciences Inc share price to rise to 5.00 in the next year from the last price of 2.21.
High126.2%5.00
Med126.2%5.00
Low126.2%5.00

Earnings history & estimates in USD

On Nov 05, 2024, Minerva Neurosciences Inc reported 3rd quarter 2024 losses of -0.540 per share. This result exceeded the -1.01 consensus loss of the one analyst covering the company and exceeded last year's 3rd quarter results by 47.57%.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate+9.44%
Minerva Neurosciences Inc reported annual 2023 losses of -4.61 per share on Feb 22, 2024.
Average growth rate+29.54%
More ▼

Revenue history & estimates in USD

Minerva Neurosciences, Inc. did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Minerva Neurosciences, Inc. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate-33.33%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.